{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T23:55:32Z","timestamp":1791849332999,"version":"4.3.4"},"reference-count":83,"publisher":"Rockefeller University Press","issue":"10","license":[{"start":{"date-parts":[[2024,9,5]],"date-time":"2024-09-05T00:00:00Z","timestamp":1725494400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.rupress.org\/terms\/"},{"start":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T00:00:00Z","timestamp":1741219200000},"content-version":"vor","delay-in-days":182,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0\/"}],"funder":[{"name":"Australian Research Council Centre of Excellence for the Mathematical Analysis of Cellular Systems","award":["CE230100001"],"award-info":[{"award-number":["CE230100001"]}],"id":[{"id":"https:\/\/ror.org\/05mmh0f86","id-type":"ROR","asserted-by":"crossref"}]},{"DOI":"10.13039\/100005189","name":"Leukemia and Lymphoma Society","doi-asserted-by":"publisher","award":["LLS SCOR 7021-20"],"award-info":[{"award-number":["LLS SCOR 7021-20"]}],"id":[{"id":"10.13039\/100005189","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005189","name":"Leukemia and Lymphoma Society","doi-asserted-by":"publisher","award":["LLS SCOR 7027-23"],"award-info":[{"award-number":["LLS SCOR 7027-23"]}],"id":[{"id":"10.13039\/100005189","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005189","name":"Leukemia and Lymphoma Society","doi-asserted-by":"publisher","award":["LLS SCOR 7029-23"],"award-info":[{"award-number":["LLS SCOR 7029-23"]}],"id":[{"id":"10.13039\/100005189","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001384","name":"Sam Waxman Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001384","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002012","name":"Chemotherapy Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002012","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Institute for Follicular Lymphoma Innovation"},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P50 CA217694"],"award-info":[{"award-number":["P50 CA217694"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R35 CA220499"],"award-info":[{"award-number":["R35 CA220499"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P01 CA229086"],"award-info":[{"award-number":["P01 CA229086"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 CA266279"],"award-info":[{"award-number":["R01 CA266279"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007052","name":"Memorial Sloan-Kettering Cancer Center","doi-asserted-by":"publisher","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}],"id":[{"id":"10.13039\/100007052","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R35 CA252982"],"award-info":[{"award-number":["R35 CA252982"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001219","name":"Lymphoma Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001219","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009859","name":"Geoffrey Beene Cancer Research Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009859","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Starr Cancer Consortium","award":["I10-0064"],"award-info":[{"award-number":["I10-0064"]}],"id":[{"id":"https:\/\/ror.org\/009tqys91","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Follicular Lymphoma Foundation","id":[{"id":"https:\/\/ror.org\/03hr73p06","id-type":"ROR","asserted-by":"crossref"}]},{"DOI":"10.13039\/100004325","name":"Astrazeneca","doi-asserted-by":"publisher","award":["SK2021-1271"],"award-info":[{"award-number":["SK2021-1271"]}],"id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["rupress.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,10,7]]},"abstract":"<jats:p>The translocation t(14;18) activates BCL2 and is considered the initiating genetic lesion in most follicular lymphomas (FL). Surprisingly, FL patients fail to respond to the BCL2 inhibitor, Venetoclax. We show that mutations and deletions affecting the histone lysine methyltransferase SETD1B (KMT2G) occur in 7% of FLs and 16% of diffuse large B cell lymphomas (DLBCL). Deficiency in SETD1B confers striking resistance to Venetoclax and an experimental MCL-1 inhibitor. SETD1B also acts as a tumor suppressor and cooperates with the loss of KMT2D in lymphoma development in vivo. Consistently, loss of SETD1B in human lymphomas typically coincides with loss of KMT2D. Mechanistically, SETD1B is required for the expression of several proapoptotic BCL2 family proteins. Conversely, inhibitors of the KDM5 histone H3K4 demethylases restore BIM and BIK expression and synergize with Venetoclax in SETD1B-deficient lymphomas. These results establish SETD1B as an epigenetic regulator of cell death and reveal a pharmacological strategy to augment Venetoclax sensitivity in lymphoma.<\/jats:p>","DOI":"10.1084\/jem.20231143","type":"journal-article","created":{"date-parts":[[2024,8,3]],"date-time":"2024-08-03T02:20:45Z","timestamp":1722651645000},"update-policy":"https:\/\/doi.org\/10.1084\/jem.crossmarkpolicy","source":"Crossref","is-referenced-by-count":11,"title":["<i>SETD1B<\/i>\n                    mutations confer apoptosis resistance and BCL2 independence in B cell lymphoma"],"prefix":"10.1084","volume":"221","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0518-9554","authenticated-orcid":true,"given":"Ana","family":"Portelinha","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02yrq0923","id-type":"ROR","asserted-by":"publisher"}],"name":"Cancer Biology and Genetics Program, Memorial Sloan-Kettering Cancer Center 1 , New York, NY,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0601-2075","authenticated-orcid":true,"given":"Shenqiu","family":"Wang","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02yrq0923","id-type":"ROR","asserted-by":"publisher"}],"name":"Cancer Biology and Genetics Program, Memorial Sloan-Kettering Cancer Center 1 , New York, NY,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-1799-8874","authenticated-orcid":true,"given":"Sara","family":"Parsa","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02yrq0923","id-type":"ROR","asserted-by":"publisher"}],"name":"Cancer Biology and Genetics Program, Memorial Sloan-Kettering Cancer Center 1 , New York, NY,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1818-7427","authenticated-orcid":true,"given":"Man","family":"Jiang","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02yrq0923","id-type":"ROR","asserted-by":"publisher"}],"name":"Cancer Biology and Genetics Program, Memorial Sloan-Kettering Cancer Center 1 , New York, NY,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6736-8246","authenticated-orcid":true,"given":"Alexander N.","family":"Gorelick","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02yrq0923","id-type":"ROR","asserted-by":"publisher"}],"name":"Human Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center 2 , New York, NY,","place":["USA"]},{"id":[{"id":"https:\/\/ror.org\/03wevmz92","id-type":"ROR","asserted-by":"publisher"}],"name":"Harvard Medical School 3 Department of Genetics, , Boston, MA,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7935-7798","authenticated-orcid":true,"given":"Sagarajit","family":"Mohanty","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02yrq0923","id-type":"ROR","asserted-by":"publisher"}],"name":"Cancer Biology and Genetics Program, Memorial Sloan-Kettering Cancer Center 1 , New York, NY,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-7650-3720","authenticated-orcid":true,"given":"Soumya","family":"Sharma","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02yrq0923","id-type":"ROR","asserted-by":"publisher"}],"name":"Cancer Biology and Genetics Program, Memorial Sloan-Kettering Cancer Center 1 , New York, NY,","place":["USA"]},{"id":[{"id":"https:\/\/ror.org\/02r109517","id-type":"ROR","asserted-by":"publisher"}],"name":"Weill Cornell Medicine 4 Department of Physiology and Biophysics, , New York, NY,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3873-315X","authenticated-orcid":true,"given":"Elisa","family":"de Stanchina","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02yrq0923","id-type":"ROR","asserted-by":"publisher"}],"name":"Antitumor Assessment Core, Memorial Sloan Kettering Cancer Center 5 , New York, NY,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-1872-6522","authenticated-orcid":true,"given":"Marjan","family":"Berishaj","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02yrq0923","id-type":"ROR","asserted-by":"publisher"}],"name":"Cancer Biology and Genetics Program, Memorial Sloan-Kettering Cancer Center 1 , New York, NY,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-1229-0756","authenticated-orcid":true,"given":"Chunying","family":"Zhao","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02yrq0923","id-type":"ROR","asserted-by":"publisher"}],"name":"Cancer Biology and Genetics Program, Memorial Sloan-Kettering Cancer Center 1 , New York, NY,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4022-1532","authenticated-orcid":true,"given":"James","family":"Heward","sequence":"additional","affiliation":[{"name":"Nucleome Therapeutics 6 , Oxford,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4643-7078","authenticated-orcid":true,"given":"Neeraj K.","family":"Aryal","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/043cec594","id-type":"ROR","asserted-by":"publisher"}],"name":"Bioscience, Early Oncology R&D, AstraZeneca 7 , Waltham, MA,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8401-4546","authenticated-orcid":true,"given":"Omid","family":"Tavana","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/043cec594","id-type":"ROR","asserted-by":"publisher"}],"name":"Bioscience, Early Oncology R&D, AstraZeneca 7 , Waltham, MA,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1249-6456","authenticated-orcid":true,"given":"Jiayu","family":"Wen","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/019wvm592","id-type":"ROR","asserted-by":"publisher"}],"name":"The John Curtin School of Medical Research, The Australian National University and Australian Research Council Centre of Excellence for the Mathematical Analysis of Cellular Systems 8 Division of Genome Sciences and Cancer, , Canberra,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9069-1866","authenticated-orcid":true,"given":"Jude","family":"Fitzgibbon","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/043cec594","id-type":"ROR","asserted-by":"publisher"}],"name":"Haematology R&D, AstraZeneca 9 , Waltham, MA,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6576-5256","authenticated-orcid":true,"given":"Ahmet","family":"Dogan","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02yrq0923","id-type":"ROR","asserted-by":"publisher"}],"name":"Hematopathology Service, Memorial Sloan-Kettering Cancer Center 10 Departments of Pathology and Laboratory Medicine, , New York, NY,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0001-4133","authenticated-orcid":true,"given":"Anas","family":"Younes","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/043cec594","id-type":"ROR","asserted-by":"publisher"}],"name":"Haematology R&D, AstraZeneca 11 , New York, NY,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8074-2287","authenticated-orcid":true,"given":"Ari M.","family":"Melnick","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02r109517","id-type":"ROR","asserted-by":"publisher"}],"name":"New York Presbyterian Hospital, Weill Cornell Medicine 12 Hematology and Oncology Division, Medicine Department, , New York, NY,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4608-222X","authenticated-orcid":true,"given":"Hans-Guido","family":"Wendel","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02yrq0923","id-type":"ROR","asserted-by":"publisher"}],"name":"Cancer Biology and Genetics Program, Memorial Sloan-Kettering Cancer Center 1 , New York, NY,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"291","published-online":{"date-parts":[[2024,9,5]]},"reference":[{"key":"2026101219313932000_bib1","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1038\/s41591-018-0243-z","article-title":"Dynamic molecular monitoring reveals that SWI-SNF mutations mediate resistance to ibrutinib plus venetoclax in mantle cell lymphoma","volume":"25","author":"Agarwal","year":"2019","journal-title":"Nat. Med."},{"key":"2026101219313932000_bib2","doi-asserted-by":"publisher","first-page":"77","DOI":"10.2217\/epi.15.96","article-title":"Epigenetic dysregulation in follicular lymphoma","volume":"8","author":"Araf","year":"2016","journal-title":"Epigenomics"},{"key":"2026101219313932000_bib3","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1038\/s41408-020-00389-w","article-title":"Genetic and epigenetic determinants of diffuse large B-cell lymphoma","volume":"10","author":"Bakhshi","year":"2020","journal-title":"Blood Cancer J."},{"key":"2026101219313932000_bib4","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1242\/dev.098152","article-title":"The H3K4 methyltransferase Setd1a is first required at the epiblast stage, whereas Setd1b becomes essential after gastrulation","volume":"141","author":"Bledau","year":"2014","journal-title":"Development"},{"key":"2026101219313932000_bib5","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1158\/2159-8290.CD-18-1119","article-title":"Acquisition of the recurrent Gly101Val mutation in BCL2 confers resistance to venetoclax in patients with progressive chronic lymphocytic leukemia","volume":"9","author":"Blombery","year":"2019","journal-title":"Cancer Discov."},{"key":"2026101219313932000_bib6","doi-asserted-by":"publisher","first-page":"e188","DOI":"10.1111\/bjh.16069","article-title":"Characterization of a novel venetoclax resistance mutation (BCL2 Phe104Ile) observed in follicular lymphoma","volume":"186","author":"Blombery","year":"2019","journal-title":"Br. J. Haematol."},{"key":"2026101219313932000_bib7","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.cell.2016.08.032","article-title":"Loss of the HVEM tumor suppressor in lymphoma and restoration by modified CAR-T cells","volume":"167","author":"Boice","year":"2016","journal-title":"Cell"},{"key":"2026101219313932000_bib8","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1038\/s43018-021-00264-y","article-title":"Mitochondrial inhibitors circumvent adaptive resistance to venetoclax and cytarabine combination therapy in acute myeloid leukemia","volume":"2","author":"Bosc","year":"2021","journal-title":"Nat. Cancer"},{"key":"2026101219313932000_bib9","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/leu.2016.175","article-title":"Combined copy number and mutation analysis identifies oncogenic pathways associated with transformation of follicular lymphoma","volume":"31","author":"Bouska","year":"2017","journal-title":"Leukemia"},{"key":"2026101219313932000_bib10","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1016\/j.celrep.2014.02.004","article-title":"Histone demethylase RBP2 is critical for breast cancer progression and metastasis","volume":"6","author":"Cao","year":"2014","journal-title":"Cell Rep."},{"key":"2026101219313932000_bib11","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","article-title":"The cBio cancer genomics portal: An open platform for exploring multidimensional cancer genomics data","volume":"2","author":"Cerami","year":"2012","journal-title":"Cancer Discov."},{"key":"2026101219313932000_bib12","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1038\/s41591-018-0016-8","article-title":"Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes","volume":"24","author":"Chapuy","year":"2018","journal-title":"Nat. Med."},{"key":"2026101219313932000_bib13","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1158\/0008-5472.CAN-09-1947","article-title":"Drug combination studies and their synergy quantification using the Chou-Talalay method","volume":"70","author":"Chou","year":"2010","journal-title":"Cancer Res."},{"key":"2026101219313932000_bib14","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1016\/j.cell.2007.02.003","article-title":"RBP2 belongs to a family of demethylases, specific for tri-and dimethylated lysine 4 on histone 3","volume":"128","author":"Christensen","year":"2007","journal-title":"Cell"},{"key":"2026101219313932000_bib15","doi-asserted-by":"publisher","first-page":"2094","DOI":"10.1182\/blood.2022017341","article-title":"Mechanisms of resistance to venetoclax","volume":"140","author":"Condoluci","year":"2022","journal-title":"Blood"},{"key":"2026101219313932000_bib16","doi-asserted-by":"publisher","first-page":"4690","DOI":"10.1158\/1078-0432.CCR-20-4842","article-title":"Long-term follow-up of patients with relapsed or refractory non-hodgkin lymphoma treated with venetoclax in a phase I, first-in-human study","volume":"27","author":"Davids","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"2026101219313932000_bib17","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1200\/JCO.2016.70.4320","article-title":"Phase I first-in-human study of venetoclax in patients with relapsed or refractory non-hodgkin lymphoma","volume":"35","author":"Davids","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"2026101219313932000_bib18","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1038\/352251a0","article-title":"Cloning of cDNAs for cellular proteins that bind to the retinoblastoma gene product","volume":"352","author":"Defeo-Jones","year":"1991","journal-title":"Nature"},{"key":"2026101219313932000_bib19","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.critrevonc.2009.01.002","article-title":"Molecular classification of T-cell lymphomas","volume":"72","author":"de Leval","year":"2009","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"2026101219313932000_bib20","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1038\/s41467-020-14620-6","article-title":"Genetic screens in isogenic mammalian cell lines without single cell cloning","volume":"11","author":"DeWeirdt","year":"2020","journal-title":"Nat. Commun."},{"key":"2026101219313932000_bib21","doi-asserted-by":"publisher","first-page":"2276","DOI":"10.1182\/blood-2003-07-2469","article-title":"VavP-Bcl2 transgenic mice develop follicular lymphoma preceded by germinal center hyperplasia","volume":"103","author":"Egle","year":"2004","journal-title":"Blood"},{"key":"2026101219313932000_bib22","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/s0960-9822(00)00129-9","article-title":"Analysis of the B-cell progenitor compartment at the level of single cells","volume":"4","author":"Ehlich","year":"1994","journal-title":"Curr. Biol."},{"key":"2026101219313932000_bib23","first-page":"3149","article-title":"Characterization of the retinoblastoma binding proteins RBP1 and RBP2","volume":"8","author":"Fattaey","year":"1993","journal-title":"Oncogene"},{"key":"2026101219313932000_bib24","doi-asserted-by":"publisher","first-page":"pl1","DOI":"10.1126\/scisignal.2004088","article-title":"Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal","volume":"6","author":"Gao","year":"2013","journal-title":"Sci. Signal."},{"key":"2026101219313932000_bib25","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1002\/gcc.20856","article-title":"Integrative genomic profiling reveals conserved genetic mechanisms for tumorigenesis in common entities of non-Hodgkin\u2019s lymphoma","volume":"50","author":"Green","year":"2011","journal-title":"Genes Chromosomes Cancer"},{"key":"2026101219313932000_bib26","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1016\/j.trecan.2017.08.004","article-title":"JARID1 histone demethylases: Emerging targets in cancer","volume":"3","author":"Harmeyer","year":"2017","journal-title":"Trends Cancer"},{"key":"2026101219313932000_bib27","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/j.molcel.2010.05.004","article-title":"Simple combinations of lineage-determining transcription factors prime cis-regulatory elements required for macrophage and B cell identities","volume":"38","author":"Heinz","year":"2010","journal-title":"Mol. Cell"},{"key":"2026101219313932000_bib28","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1182\/blood.2020008743","article-title":"KDM5 inhibition offers a novel therapeutic strategy for the treatment of KMT2D mutant lymphomas","volume":"138","author":"Heward","year":"2021","journal-title":"Blood"},{"key":"2026101219313932000_bib29","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1038\/nrd4154","article-title":"Histone lysine demethylases as targets for anticancer therapy","volume":"12","author":"H\u00f8jfeldt","year":"2013","journal-title":"Nat. Rev. Drug Discov."},{"key":"2026101219313932000_bib30","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1038\/nrc.2017.127","article-title":"From genetics to the clinic: A translational perspective on follicular lymphoma","volume":"18","author":"Huet","year":"2018","journal-title":"Nat. Rev. Cancer"},{"key":"2026101219313932000_bib31","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1016\/j.cell.2007.02.017","article-title":"The X-linked mental retardation gene SMCX\/JARID1C defines a family of histone H3 lysine 4 demethylases","volume":"128","author":"Iwase","year":"2007","journal-title":"Cell"},{"key":"2026101219313932000_bib32","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1158\/2159-8290.CD-16-0975","article-title":"CREBBP inactivation promotes the development of HDAC3-dependent lymphomas","volume":"7","author":"Jiang","year":"2017","journal-title":"Cancer Discov."},{"key":"2026101219313932000_bib33","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1016\/j.stem.2020.07.021","article-title":"Nicotinamide metabolism mediates resistance to venetoclax in relapsed acute myeloid leukemia stem cells","volume":"27","author":"Jones","year":"2020","journal-title":"Cell Stem Cell"},{"key":"2026101219313932000_bib34","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1038\/s41587-019-0201-4","article-title":"Graph-based genome alignment and genotyping with HISAT2 and HISAT-genotype","volume":"37","author":"Kim","year":"2019","journal-title":"Nat. Biotechnol."},{"key":"2026101219313932000_bib35","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1038\/nsmb1107-1058","article-title":"Histone H3 Arg2 methylation provides alternative directions for COMPASS","volume":"14","author":"Klose","year":"2007","journal-title":"Nat. Struct. Mol. Biol."},{"key":"2026101219313932000_bib36","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1038\/nature19830","article-title":"The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models","volume":"538","author":"Kotschy","year":"2016","journal-title":"Nature"},{"key":"2026101219313932000_bib37","doi-asserted-by":"publisher","first-page":"194578","DOI":"10.1016\/j.bbagrm.2020.194578","article-title":"The role of SETD1A and SETD1B in development and disease","volume":"1863","author":"Kranz","year":"2020","journal-title":"Biochim. Biophys. Acta. Gene Regul. Mech."},{"key":"2026101219313932000_bib38","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1002\/ajh.26809","article-title":"Targeting MCL-1 and BCL-2 with polatuzumab vedotin and venetoclax overcomes treatment resistance in R\/R non-Hodgkin lymphoma: Results from preclinical models and a Phase Ib study","volume":"98","author":"Lasater","year":"2023","journal-title":"Am. J. Hematol."},{"key":"2026101219313932000_bib39","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1016\/j.cell.2013.01.052","article-title":"H3K4me3 interactions with TAF3 regulate preinitiation complex assembly and selective gene activation","volume":"152","author":"Lauberth","year":"2013","journal-title":"Cell"},{"key":"2026101219313932000_bib40","doi-asserted-by":"publisher","first-page":"3879","DOI":"10.1073\/pnas.1121343109","article-title":"Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing","volume":"109","author":"Lohr","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2026101219313932000_bib41","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1186\/s13059-014-0550-8","article-title":"Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2","volume":"15","author":"Love","year":"2014","journal-title":"Genome Biol."},{"key":"2026101219313932000_bib42","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/nature10351","article-title":"Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma","volume":"476","author":"Morin","year":"2011","journal-title":"Nature"},{"key":"2026101219313932000_bib43","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1182\/blood-2013-02-483727","article-title":"Mutational and structural analysis of diffuse large B-cell lymphoma using whole-genome sequencing","volume":"122","author":"Morin","year":"2013","journal-title":"Blood"},{"key":"2026101219313932000_bib44","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1182\/blood.2020006578","article-title":"A phase 2 study of venetoclax plus R-CHOP as first-line treatment for patients with diffuse large B-cell lymphoma","volume":"137","author":"Morschhauser","year":"2021","journal-title":"Blood"},{"key":"2026101219313932000_bib45","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1158\/2159-8290.CD-19-0125","article-title":"The TP53 apoptotic network is a primary mediator of resistance to BCL2 inhibition in AML cells","volume":"9","author":"Nechiporuk","year":"2019","journal-title":"Cancer Discov."},{"key":"2026101219313932000_bib83","doi-asserted-by":"publisher","first-page":"3812","DOI":"10.1093\/nar\/gkg509","article-title":"SIFT: Predicting amino acid changes that affect protein function.","volume":"31","author":"Ng","year":"2003","journal-title":"Nucleic Acids Res."},{"key":"2026101219313932000_bib46","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1158\/2643-3230.BCD-20-0108","article-title":"Lysine demethylase 5A is required for MYC driven transcription in multiple myeloma","volume":"2","author":"Ohguchi","year":"2021","journal-title":"Blood Cancer Discov."},{"key":"2026101219313932000_bib47","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1038\/ng.2856","article-title":"Integrated genomic analysis identifies recurrent mutations and evolution patterns driving the initiation and progression of follicular lymphoma","volume":"46","author":"Okosun","year":"2013","journal-title":"Nat. Genet."},{"key":"2026101219313932000_bib48","doi-asserted-by":"publisher","first-page":"3576","DOI":"10.3390\/cancers14153576","article-title":"Real-world experience of measurable residual disease response and prognosis in acute myeloid leukemia treated with venetoclax and azacitidine","volume":"14","author":"Ong","year":"2022","journal-title":"Cancers"},{"key":"2026101219313932000_bib49","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1016\/j.cell.2011.09.035","article-title":"The Eph-receptor A7 is a soluble tumor suppressor for follicular lymphoma","volume":"147","author":"Oricchio","year":"2011","journal-title":"Cell"},{"key":"2026101219313932000_bib50","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1038\/nm.3943","article-title":"The histone lysine methyltransferase KMT2D sustains a gene expression program that represses B cell lymphoma development","volume":"21","author":"Ortega-Molina","year":"2015","journal-title":"Nat. Med."},{"key":"2026101219313932000_bib51","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1038\/s41588-021-00887-y","article-title":"The HIF complex recruits the histone methyltransferase SET1B to activate specific hypoxia-inducible genes","volume":"53","author":"Ortmann","year":"2021","journal-title":"Nat. Genet."},{"key":"2026101219313932000_bib52","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1038\/s43018-020-0080-0","article-title":"The serine hydroxymethyltransferase-2 (SHMT2) initiates lymphoma development through epigenetic tumor suppressor silencing","volume":"1","author":"Parsa","year":"2020","journal-title":"Nat. Cancer"},{"key":"2026101219313932000_bib53","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1038\/ng.892","article-title":"Analysis of the coding genome of diffuse large B-cell lymphoma","volume":"43","author":"Pasqualucci","year":"2011","journal-title":"Nat. Genet."},{"key":"2026101219313932000_bib54","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1016\/j.cell.2014.09.014","article-title":"CRISPR-Cas9 knockin mice for genome editing and cancer modeling","volume":"159","author":"Platt","year":"2014","journal-title":"Cell"},{"key":"2026101219313932000_bib55","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/j.cell.2017.09.027","article-title":"Genetic and functional drivers of diffuse large B Cell lymphoma","volume":"171","author":"Reddy","year":"2017","journal-title":"Cell"},{"key":"2026101219313932000_bib56","doi-asserted-by":"crossref","first-page":"2902","DOI":"10.1200\/JCO.2009.26.1693","article-title":"Prognostic factors in follicular lymphoma","volume":"28","author":"Relander","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"2026101219313932000_bib57","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1515\/hsz-2016-0107","article-title":"iBH3: simple, fixable BH3 profiling to determine apoptotic priming in primary tissue by flow cytometry","volume":"397","author":"Ryan","year":"2016","journal-title":"Biol. Chem."},{"key":"2026101219313932000_bib58","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.cell.2018.03.035","article-title":"Oncogenic signaling pathways in the cancer genome Atlas","volume":"173","author":"Sanchez-Vega","year":"2018","journal-title":"Cell"},{"key":"2026101219313932000_bib59","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1038\/nmeth.3047","article-title":"Improved vectors and genome-wide libraries for CRISPR screening","volume":"11","author":"Sanjana","year":"2014","journal-title":"Nat. Methods"},{"key":"2026101219313932000_bib60","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.27157","article-title":"The H3K4 methyltransferase Setd1b is essential for hematopoietic stem and progenitor cell homeostasis in mice","volume":"7","author":"Schmidt","year":"2018","journal-title":"Elife"},{"key":"2026101219313932000_bib61","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1056\/NEJMoa1801445","article-title":"Genetics and pathogenesis of diffuse large B-cell lymphoma","volume":"378","author":"Schmitz","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"2026101219313932000_bib62","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.4161\/cc.6.11.4269","article-title":"The function and regulation of the JARID1 family of histone H3 lysine 4 demethylases: The Myc connection","volume":"6","author":"Secombe","year":"2007","journal-title":"Cell Cycle"},{"key":"2026101219313932000_bib63","doi-asserted-by":"publisher","first-page":"5197","DOI":"10.1021\/jm100217a","article-title":"(Bis)urea and (bis)thiourea inhibitors of lysine-specific demethylase 1 as epigenetic modulators","volume":"53","author":"Sharma","year":"2010","journal-title":"J. Med. Chem."},{"key":"2026101219313932000_bib64","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1146\/annurev-biochem-051710-134100","article-title":"The COMPASS family of histone H3K4 methylases: Mechanisms of regulation in development and disease pathogenesis","volume":"81","author":"Shilatifard","year":"2012","journal-title":"Annu. Rev. Biochem."},{"key":"2026101219313932000_bib65","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/nm.3048","article-title":"ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets","volume":"19","author":"Souers","year":"2013","journal-title":"Nat. Med."},{"key":"2026101219313932000_bib66","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1038\/s43018-020-00126-z","article-title":"Fatty acid metabolism underlies venetoclax resistance in acute myeloid leukemia stem cells","volume":"1","author":"Stevens","year":"2020","journal-title":"Nat. Cancer"},{"key":"2026101219313932000_bib67","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abo6891","article-title":"The path to venetoclax resistance is paved with mutations, metabolism, and more","volume":"14","author":"Sullivan","year":"2022","journal-title":"Sci. Transl. Med."},{"key":"2026101219313932000_bib68","doi-asserted-by":"publisher","first-page":"4711","DOI":"10.1158\/0008-5472.CAN-12-3165","article-title":"Histone demethylase RBP2 promotes lung tumorigenesis and cancer metastasis","volume":"73","author":"Teng","year":"2013","journal-title":"Cancer Res."},{"key":"2026101219313932000_bib69","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1182\/blood.2021014304","article-title":"Deregulation and epigenetic modification of BCL2-family genes cause resistance to venetoclax in hematologic malignancies","volume":"140","author":"Thomalla","year":"2022","journal-title":"Blood"},{"key":"2026101219313932000_bib70","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.chembiol.2017.02.006","article-title":"Potent and selective KDM5 inhibitor stops cellular Demethylation of H3K4me3 at transcription start sites and proliferation of MM1S myeloma cells","volume":"24","author":"Tumber","year":"2017","journal-title":"Cell Chem. Biol."},{"key":"2026101219313932000_bib71","doi-asserted-by":"publisher","first-page":"395","DOI":"10.2217\/epi.10.11","article-title":"Grasping trimethylation of histone H3 at lysine 4","volume":"2","author":"Vermeulen","year":"2010","journal-title":"Epigenomics"},{"key":"2026101219313932000_bib72","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/j.jclinepi.2006.12.009","article-title":"ICD-10 adaptations of the Ontario acute myocardial infarction mortality prediction rules performed as well as the original versions","volume":"60","author":"Vermeulen","year":"2007","journal-title":"J. Clin. Epidemiol."},{"key":"2026101219313932000_bib73","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1038\/nchembio.2085","article-title":"An inhibitor of KDM5 demethylases reduces survival of drug-tolerant cancer cells","volume":"12","author":"Vinogradova","year":"2016","journal-title":"Nat. Chem. Biol."},{"key":"2026101219313932000_bib74","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.ccell.2022.12.002","article-title":"Modulation of RNA splicing enhances response to BCL2 inhibition in leukemia","volume":"41","author":"Wang","year":"2023","journal-title":"Cancer Cell"},{"key":"2026101219313932000_bib75","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1038\/s41586-023-05780-8","article-title":"H3K4me3 regulates RNA polymerase II promoter-proximal pause-release","volume":"615","author":"Wang","year":"2023","journal-title":"Nature"},{"key":"2026101219313932000_bib76","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1038\/ng.268","article-title":"The lysine demethylase LSD1 (KDM1) is required for maintenance of global DNA methylation","volume":"41","author":"Wang","year":"2009","journal-title":"Nat. Genet."},{"key":"2026101219313932000_bib77","doi-asserted-by":"publisher","first-page":"2035","DOI":"10.1038\/ncomms3035","article-title":"A small molecule modulates Jumonji histone demethylase activity and selectively inhibits cancer growth","volume":"4","author":"Wang","year":"2013","journal-title":"Nat. Commun."},{"key":"2026101219313932000_bib78","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.232835","article-title":"Acquisition of the recurrent Gly101Val mutation in BCL2 confers resistance to venetoclax in patients with progressive chronic lymphocytic leukemia (Comment to Tausch et al.)","volume":"104","author":"Weiss","year":"2019","journal-title":"Haematologica"},{"key":"2026101219313932000_bib79","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1038\/nature02369","article-title":"Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy","volume":"428","author":"Wendel","year":"2004","journal-title":"Nature"},{"key":"2026101219313932000_bib80","doi-asserted-by":"publisher","first-page":"1964","DOI":"10.1182\/blood-2018-11-880526","article-title":"Venetoclax plus R- or G-CHOP in non-hodgkin lymphoma: Results from the CAVALLI phase 1b trial","volume":"133","author":"Zelenetz","year":"2019","journal-title":"Blood"},{"key":"2026101219313932000_bib81","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1038\/nm.3940","article-title":"Disruption of KMT2D perturbs germinal center B cell development and promotes lymphomagenesis","volume":"21","author":"Zhang","year":"2015","journal-title":"Nat. Med."},{"key":"2026101219313932000_bib82","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1038\/s41392-021-00870-3","article-title":"Activation of RAS\/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemia","volume":"7","author":"Zhang","year":"2022","journal-title":"Signal Transduct. Target. Ther."}],"container-title":["Journal of Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/rupress.org\/jem\/article-pdf\/doi\/10.1084\/jem.20231143\/1932198\/jem_20231143.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/rupress.org\/jem\/article-pdf\/doi\/10.1084\/jem.20231143\/1932198\/jem_20231143.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T23:31:43Z","timestamp":1791847903000},"score":1,"resource":{"primary":{"URL":"https:\/\/rupress.org\/jem\/article\/221\/10\/e20231143\/276954\/SETD1B-mutations-confer-apoptosis-resistance-and"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,5]]},"references-count":83,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10,7]]}},"URL":"https:\/\/doi.org\/10.1084\/jem.20231143","relation":{},"ISSN":["0022-1007","1540-9538"],"issn-type":[{"value":"0022-1007","type":"print"},{"value":"1540-9538","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,5]]},"article-number":"e20231143"}}